Bleeding After Robot-assisted Radical Prostatectomy: a Respective Study
UROBLOOD01
Evaluation of Operative Bleeding After Robot-assisted Radical Prostatectomy
1 other identifier
observational
194
1 country
1
Brief Summary
Nowadays robot-assisted radical prostatectomy (RARP) has become the standard surgical treatment for localised prostate cancer. The robotic approach has been proven superior to open retropubic prostatectomy (ORP) in terms of surgical-related morbidity: RARP has in fact been associated with significantly lower estimated blood loos (EBL), lower transfusion rate, less length of stay, shorter catheterization time, lower risk of Clavien-Dindo grade II and III complications, lower risk of vesicourethral anastomotic stricture and less post-operative pain. The optimal anatomical visualisation and the extraordinary maneuverability, along with the tamponade effect of the pneumoperitoneum, are surely to be deemed responsible of this statistically significant differences. However, to this day no study has ever investigated the prognostic significance of haematological parameters in terms of predicting perioperative bleeding risk in patients undergoing RARP. Therefore, the investigators conducted a retrospective non-interventional cohort study to gather evidence concerning the impact of anemia and thrombocytopenia on bleeding risk following this surgical procedure. Furthermore, the investigators evaluated associations between demographical, pathological and surgical factors and hemorrhagic complications. The investigators retrospectively evaluated all the patients that underwent robot-assisted radical prostatectomy in our Urology Unit from the 1st of January 2017 to the 31th of December 2020. The investigators collected demographic, clinical and pathological data from the medical records of these patients, with particular attention to other known risk-factors for RARP-associated bleeding (e.g.: volume of the prostate, body mass index, smoking status, nerve sparing technique). Complications were analyzed according to the Clavien- Dindo classification. Bleeding was assessed by considering both the hemoglobin (Hb) drop after surgery and the fluid intraoperatively collected in the suction canister, with all the due adjustments. Moreover, post-operative haemorrhagic complications were evaluated. The investigators included patients not younger than 18 years old, of which records of a pre-operative full blood count in the 30 days prior to the surgery along with a full blood count the day after were available. Criteria for exclusion were a history of congenital coagulopathies and/or congenital thrombocytopenia and patients that underwent salvage radical prostatectomy after radiation therapy. Statistics: EBL and operative time learning curve is studied. Clinical, pathological, intraoperative risk factors analysis for higher EBL is performed by linear regression modelling. Factors are evaluated independently and jointly. Association between each factor above and post-operative outcomes (i.e. post-op bleeding, need of transfusion and hematuria) is also assessed.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Dec 2022
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2023
CompletedFirst Submitted
Initial submission to the registry
February 28, 2024
CompletedFirst Posted
Study publicly available on registry
March 7, 2024
CompletedMarch 8, 2024
March 1, 2024
1 month
February 28, 2024
March 6, 2024
Conditions
Outcome Measures
Primary Outcomes (4)
Influence of hemoglobin value on haemorrhagic complications
prevalence of post-operative haemorrhagic complications stratifying by presence/absence of anaemia (evaluated in g/dl)
4 years
Influence of hematocrit value on haemorrhagic complications
prevalence of post-operative haemorrhagic complications stratifying by pre-operative hematocrit value expressed in %
4 years
Influence of platelet count on haemorrhagic complications
prevalence of post-operative haemorrhagic complications stratifying by presence/absence of thrombocytopenia (evaluated in10\^9/L)
4 years
Influence of blood group on haemorrhagic complications
prevalence of post-operative haemorrhagic complications stratifying patients by blood group
4 years
Secondary Outcomes (1)
Identification of possibile demographic and surgical predictive factors of haemorrhagic complications
4 years
Interventions
surgical removal of the entire prostate and the seminal vesicles, followed by the vescico-urethral anastomosis to restore the continuity of the lower urinary tract performed using Da Vinci Si and Xi Surgical System (Intuitive Surgical, Sunnyvale, California, USA)
Eligibility Criteria
\- Consecutive patients aged 18 years or older undergoing RARP at the Urology Unit between 1 January 2017 and 31 December 2020.
You may qualify if:
- Consecutive patients aged 18 years or older undergoing RARP at the Urology Unit between 1 January 2017 and 31 December 2020.
- All patients with a pre-operative complete blood count (CBC) in the last 30 days before surgery and a postoperative first-day CBC will be included.
You may not qualify if:
- Patients with congenital coagulation defects or congenital thrombocytopenias
- Patients undergoing salvage radical prostatectomy (post-radiotherapy)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico
Milan, 20122, Italy
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
February 28, 2024
First Posted
March 7, 2024
Study Start
December 1, 2022
Primary Completion
January 1, 2023
Study Completion
January 1, 2023
Last Updated
March 8, 2024
Record last verified: 2024-03